Drug eruption – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:34:57 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Drug eruption – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Title: Study of TAR-0520 gel for skin rash (folliculitis) caused by cancer treatment with EGFR inhibitors in colorectal cancer patients https://clinicaltrials.eu/trial/study-on-tar-0520-gel-for-treating-skin-rash-in-colorectal-cancer-patients-using-egfr-inhibitors/ Wed, 29 Apr 2026 14:57:52 +0000 https://clinicaltrials.eu/trial/study-on-tar-0520-gel-for-treating-skin-rash-in-colorectal-cancer-patients-using-egfr-inhibitors/ This study focuses on treating EGFR inhibitor-induced folliculitis, a skin condition that occurs as a side effect in patients receiving cancer treatments called EGFR inhibitors. This condition typically appears as an acne-like rash on the face and chest of patients who are receiving treatments such as cetuximab or panitumumab for colorectal cancer.

The research evaluates a new medication called TAR-0520 gel, which contains brimonidine tartrate as its active ingredient. This gel is designed to be applied directly to the skin of the face and chest. The study aims to confirm that this treatment is well-tolerated by patients who are experiencing skin reactions from their cancer treatment.

During the study, participants will use either TAR-0520 gel or a placebo gel on their skin for 28 days. The gel needs to be applied to affected areas of the face and chest, with a maximum daily amount of 1.6 grams. The total amount of gel used throughout the entire treatment period will not exceed 44.8 grams.

]]>